Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.

Different effects of biological drugs in rheumatoid arthritis / F. Atzeni, M. Benucci, S. Salli, S. Bongiovanni, L. Boccassini, P. Sarzi-Puttini. - In: AUTOIMMUNITY REVIEWS. - ISSN 1568-9972. - 12:5(2013 Mar), pp. 575-579. [10.1016/j.autrev.2012.10.020]

Different effects of biological drugs in rheumatoid arthritis

S. Bongiovanni;P. Sarzi-Puttini
2013

Abstract

Biological drugs have brought new hope to patients with rheumatoid arthritis (RA) in whom previously existing treatments could not control inflammation, joint destruction, or the progression of disability. The five currently available TNF blockers are approved for treating RA patients, but they have different structures, morphology, pharmacokinetic properties, and activity.Randomised clinical trials (RCTs) have shown that they improve the signs and symptoms of both early and long-standing RA and other inflammatory arthritides, prevent radiographic progression, and improve the patients' health-related quality of life. However, they are more effective in combination with methotrexate (MTX) than alone. Combined treatment is generally well tolerated, and seems to be relatively safe in the short term, as confirmed by RCTs, long-term observational studies and in clinical practice. Patients who fail to respond or develop adverse effects - when treated with one anti-TNF agent can be successfully treated with a second TNF antagonist. However, in the case of primary failure, it is possible that biological agents with a different mechanism of action may be more successful. Tocilizumab alone or in combination with MTX is more effective than MTX monotherapy in reducing disease activity over 24. weeks. Abatacept is well tolerated and retains its efficacy over time, as does rituximab in non-responders to other anti-TNF drugs. Finally, although these drugs improve the quality of life of RA patients, they considerably increase direct medical costs.
Abatacept; Anti-IL6; Anti-TNF agents; Biological drugs; Rituximab; Arthritis, Rheumatoid; Cartilage, Articular; Chondrocytes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Humans; Inflammation Mediators; Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Tumor Necrosis Factor-alpha
Settore MED/16 - Reumatologia
mar-2013
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1568997212002789-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 200.12 kB
Formato Adobe PDF
200.12 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/667650
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 81
  • ???jsp.display-item.citation.isi??? 76
social impact